1.. Introduction {#s3}
================

In a typical study, such as a clinical trial, the investigators might be interested in the difference in a pre-selected primary endpoint between an innovative treatment and a placebo control (or a standard treatment) group. Motivated by preliminary evidence that the innovative treatment may potentially benefit patients, clinical trials aim to test this hypothesis rigorously.

Before we prove that a new, experimental treatment works, we have to maintain equipoise for both treatment options in order to ethically conduct a trial. Equipoise means that there is no difference between the two treatments. This hypothesis is what we statistically refer to as the \'null hypothesis\'. In addition to the null hypothesis, all clinical trials also have a working hypothesis that the experimental treatment will not only work, but also achieve clinically significant benefits. This hypothesis is often referred to as the alternative hypothesis.

Upon completion of a trial, we examine the trial data in order to determine which hypothesis - the null hypothesis or the alternative hypothesis - is supported. In 1925 Fisher\[[@B1]\] introduced null hypothesis significance testing (NHST) to objectively separate interesting findings from background noise. The NHST is the most widely used data analysis method in most scientific disciplines.\[[@B2]\] We look at the difference between the two treatments that we observe in the trial and ask ourselves: "What is the probability of observing a difference between the groups as large as the observed one (or larger) under the equipoise (null) hypothesis?" This probability is referred to as the '*p*-value'\[[@B3]\] or 'the significance probability.' When this probability is sufficiently small, we are confident that the likelihood of no difference between treatments is very small and, thus, we conclude that the trial supports the alternative hypothesis (i.e., the working hypothesis that motivated the study). When the probability is larger, we have little evidence to support the alternative hypothesis, even though it may still be true.

In statistical hypothesis testing, two types of errors can occur: false positives (i.e., the incorrect rejection of the null hypothesis) and false negatives (i.e., the failure to reject a false null hypothesis). The NHST approach uses an arbitrary cutoff value (usually 0. 05) to control the false-positive rate. Findings with *p*-values smaller than the cutoff value are described as 'statistically significant' or 'positive,' while findings with *p*-values equal to or larger than the cutoff are described as 'nonsignificant' or 'negative.'

2.. The debate about *p*-values {#s4}
===============================

The beauty of a *p*-value is that it combines both the signal (treatment difference) and noise (random variation of the estimated signal) into a single measure of the strength of the evidence provided by the trial data. Widely adopted in the scientific research community, *p*-values are considered the most influential and transformative statistical concept in modern science. However, despite their success, there is an emerging debate about whether or not the use of *p*-values is responsible for the frequent failure to replicate statistically significant scientific findings ------ a serious problem that limits the translation of clinical research into clinical practice. In their recent paper in Nature Methods, Halsey and colleagues\[[@B4]\] argued that:

"the *P*-value is often used without the realization that in most cases the statistical power of a study is too low for P to assist the interpretation of the data. ... Researchers would do better to discard the *P*-value and use alternative statistical measures for data interpretation. "

In accordance with this thinking, the editors of the journal *Basic and Applied Social Psychology* recently banned *p*-values and hypothesis testing from articles published in their journal.\[[@B5]\]

In contrast to this view, we argue that the *p*-value alone cannot be blamed for the lack of repeatability of scientific research findings. The *p*-value is a one-dimensional metric that measures the strength of evidence as a signal-to-noise ratio in one experiment. Like all statistics, the *p*-value is estimated from the data and, thus, is subject to random variations; so its confidence interval can be pretty wide, particularly when the original data are from a relatively small sample of data points. For example, based on the work of Lazzeroni and colleagues,\[[@B6],[@B7]\] identical replication of a test with a reported one-sided *p*-value of 2. 5% would have a 95% confidence interval for the *p*-value ranging from 0 to 79%. However, the width of this confidence interval can be narrowed by increasing the sample size of the replication experiment.

One common misuse of the *p*-value unrelated to the repeatability of research results is that it is often misinterpreted by clinicians and other persons who are not trained in statistics. The *p*-value, which assesses the probability a given result is due to chance, is often incorrectly interpreted as a measure of the strength of a relationship. For example, in clinical trials smaller *p*-values are incorrectly presumed to show a greater superiority of the experimental intervention compared to the intervention (if any) in the control group. However, a tiny, clinically-insignificant effect size can be associated with very low *p*-values if the sample size is quite large. Thus, a low *p*-value does not necessarily mean that a finding is of major clinical or biological interest.

Several alternatives to *p*-values have been proposed,\[[@B8],[@B9]\] including confidence intervals and Bayesian statistics. A confidence interval provides two-dimensional information, the point estimate (signal) and the width of the confidence interval (noise), thus it can potentially be more informative than a *p*-value and should always be reported. However, confidence intervals are unit-dependent and, thus, are hard to compare between different studies. Additionally, decision rules about acceptance or rejection of the null hypothesis based on confidence intervals result in the same conclusion as decision rules based on *p*-value ------ whenever a 95% confidence interval excludes the null value of a parameter there is a corresponding *p*-value less than 0. 05. The 'Bayesian credible interval' in Bayesian statistics, analogous to the confidence interval in frequency statistics, is another possible alternative to the *p*-value.\[[@B10]\] However both of these alternative methods can, like the *p*-value, result in false positives and false negatives when deciding to accept or reject a clinical hypothesis and can be incorrectly interpreted to represent the clinical or biological importance of the finding.

3.. Banning *p*-values is not a solution for reproducible research {#s5}
==================================================================

There are many stages to the design and analysis of a successful study, including data collection, processing, and analysis. The last of these steps is the calculation of an inferential statistic, such as a *p*-value, and application of a decision rule using this statistic (e.g., p\<0. 05) to accept or reject the hypothesis of interest. In the course of collecting and analyzing data, researchers have many decisions to make, such as how much data to collect, which observations to exclude, and which conditions to combine and compare.\[[@B11]\] These decisions made before the data analysis have a much greater impact on the validity of the final results than the decision about which inferential statistic to employ.\[[@B12]\]

Simmons and colleagues\[[@B11]\] have shown that despite the nominal endorsement of a maximum false-positive rate of 5% (i.e., *p*\<0. 05), changes in a few data-analysis decisions can increase the false-positive rate to 60% in a single study. To protect against the under-estimation of the false-positive rate, they recommend the full disclosure of all data-analysis decisions and the reporting of all relevant comparisons, not only the significant ones. A more rigorous method to reduce publications with false-positive results is recommended by Gelman and Loken:\[[@B13]\] it involves conducting all studies in two stages, the first being a theory-based exploratory study and the second being a purely confirmatory study with its own pre-registered protocol that specifies in advance all the details of data processing and analysis. This approach allows for freedom and flexibility in the analysis while providing enough rigor to reduce the number of false positive results being published. It also helps distinguish the results of confirmatory analyses, which are reasonably robust, from the results of exploratory analyses, which should be treated with skepticism.\[[@B14]\]

The incentives to publish only statistically significant ('positive') results has led to publication bias, a phenomenon in which studies with positive results are more likely to be published than studies with negative results. Publication bias is a serious problem that affects both the repeatability of research results and, perhaps more importantly, the correct interpretation and translation of published research results into clinical guidelines and health policies.\[[@B15]\] However, publication bias is primarily a problem of selective publication unrelated to the use of the *p*-value; the selective reporting of positive studies can also occur when other inferential statistics such as the Bayesian critical interval are used to test the null and alternative hypotheses.\[[@B16]\] Publication bias can be reduced not by banning *p*-values, but by applying higher standards and scientifically based review processes, and by encouraging the publication of well-designed and conducted 'negative' studies.

The lack of repeatability in research cannot be blamed on the use of *p*-values. As pointed out by Leek and Peng,\[[@B12]\] "ridding science of shoddy statistics will require scrutiny at every step, not merely the last one". Clinical trial research is constructed from clearly defined null and alternative hypotheses, so the use of a *p*-value for hypothesis testing is appropriate. Banning *p*-values is not the solution to the low repeatability of scientific research findings.

So what is the main culprit that can explain poor repeatability of research findings? If we think of statistical decision-making as diagnostic tests of the scientific validity of the result generated using the data collected in a study, a *p*-value can be viewed as a lab test value (similar to a lab test to aid in the determination of a clinical diagnosis). In this analogy, one minus the *p*-value is the specificity of the 'diagnostic test', that is, the chance of accepting the null when there is no treatment effect. The statistical power is the sensitivity of the diagnostic test, the ability to correctly identify a true/valid hypothesis. However, if only a small proportion of studies undertaken have correct (true/valid) clinical hypotheses, the positive predictive value of the diagnostic/statistical test (i.e., the chance of the clinical hypothesis being true given a statistically significant test) would be low. For example, using a study design with a 5% Type I error rate (i.e., a 95% specificity) and an 80% power (sensitivity), when only 10% of the clinical hypotheses to be tested are true, the positive predictive value - the likelihood that a 'statistically significant' result is true - is merely 60% and would be even worse for designs with lower statistical power. Thus, banning *p*-values is not a solution for research that is based on questionable hypotheses. This concept was explained by Dr. loannidis\[[@B17]\] in 2005 in his famous article titled "Why most published research findings are false. " Science is an iterative learning process. There is no shortcut. As long as the proportion of true hypotheses is low among the studies undertaken or the statistical power of the undertaken studies is low (low sensitivity), the results are less likely to be repeatable. Garbage in garbage out!

To improve reproducibility of research findings, we must first rigorously apply scientific principles to generate well-defined and scientifically justified hypotheses. This requires thorough background research (often including systematic reviews) to develop protocols with a solid foundation, conducting pilot studies to prove concepts, using rigorous methods to objectively assess outcome measures, and properly sizing the clinical trials to ensure high statistical power (i.e., high sensitivity). Physicians do not diagnose a disease based on a single lab value; they rely on collective evidence that supports the diagnostic test. Similarly, the results of clinical trials and other medical research should not depend entirely on a single *p*-value for the primary endpoint; the consistency of the finding for the primary endpoint with supporting evidence from secondary endpoints and with other evidence should be taken into account. Finally, it is critically important to report study findings in an accurate, complete, and transparent way (e.g., using reporting guidelines, available at: <http://www.equator-network.org>) that makes it possible for readers who may wish to use or replicate the results to clearly understand the strengths and limitations of the study and the strengths and limitations of the statistical methods used to analyze the data generated by the study.

4.. Conclusion {#s6}
==============

In summary, the *p*-value is an acceptable inferential statistic to test hypotheses in clinical trial research. However, exclusively relying on a single *p*-value to judge the scientific merit of a study is a misuse of the *p*-value; study conclusions need to be based on a range of inter-related findings, not on a single statistical test. Understanding the limitations and variability of *p*-values is crucial to correctly interpreting trial results. Better background preparations for studies and the conduct of effective pilot studies before undertaking the main study are the most important steps that are needed to improve the validity and repeatability of scientific findings. Dropping the use of the *p*-value and of hypothesis testing due to their limitations is unlikely to have much effect on improving the repeatability of clinical trial research.
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